These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
238 related articles for article (PubMed ID: 21589947)
1. Lorcaserin for the treatment of obesity. Redman LM; Ravussin E Drugs Today (Barc); 2010 Dec; 46(12):901-10. PubMed ID: 21589947 [TBL] [Abstract][Full Text] [Related]
2. Lorcaserin: an investigational serotonin 2C agonist for weight loss. Hurren KM; Berlie HD Am J Health Syst Pharm; 2011 Nov; 68(21):2029-37. PubMed ID: 22011982 [TBL] [Abstract][Full Text] [Related]
3. Lorcaserin, a novel selective human 5-hydroxytryptamine2C agonist: in vitro and in vivo pharmacological characterization. Thomsen WJ; Grottick AJ; Menzaghi F; Reyes-Saldana H; Espitia S; Yuskin D; Whelan K; Martin M; Morgan M; Chen W; Al-Shamma H; Smith B; Chalmers D; Behan D J Pharmacol Exp Ther; 2008 May; 325(2):577-87. PubMed ID: 18252809 [TBL] [Abstract][Full Text] [Related]
4. The safety and efficacy of lorcaserin in the management of obesity. Hess R; Cross LB Postgrad Med; 2013 Nov; 125(6):62-72. PubMed ID: 24200762 [TBL] [Abstract][Full Text] [Related]
5. Lorcaserin: a novel serotonin 2C agonist for the treatment of obesity. Nigro SC; Luon D; Baker WL Curr Med Res Opin; 2013 Jul; 29(7):839-48. PubMed ID: 23574263 [TBL] [Abstract][Full Text] [Related]
6. Lorcaserin Hcl for the treatment of obesity. Shukla AP; Kumar RB; Aronne LJ Expert Opin Pharmacother; 2015; 16(16):2531-8. PubMed ID: 26472579 [TBL] [Abstract][Full Text] [Related]
7. A one-year randomized trial of lorcaserin for weight loss in obese and overweight adults: the BLOSSOM trial. Fidler MC; Sanchez M; Raether B; Weissman NJ; Smith SR; Shanahan WR; Anderson CM; J Clin Endocrinol Metab; 2011 Oct; 96(10):3067-77. PubMed ID: 21795446 [TBL] [Abstract][Full Text] [Related]
8. Lorcaserin in Obese and Overweight Patients Taking Prohibited Serotonergic Agents: A Retrospective Analysis. Nguyen CT; Zhou S; Shanahan W; Fain R Clin Ther; 2016 Jun; 38(6):1498-1509. PubMed ID: 27206567 [TBL] [Abstract][Full Text] [Related]
9. Safety and tolerability review of lorcaserin in clinical trials. Greenway FL; Shanahan W; Fain R; Ma T; Rubino D Clin Obes; 2016 Oct; 6(5):285-95. PubMed ID: 27627785 [TBL] [Abstract][Full Text] [Related]
10. Echocardiographic assessment of cardiac valvular regurgitation with lorcaserin from analysis of 3 phase 3 clinical trials. Weissman NJ; Sanchez M; Koch GG; Smith SR; Shanahan WR; Anderson CM Circ Cardiovasc Imaging; 2013 Jul; 6(4):560-7. PubMed ID: 23661689 [TBL] [Abstract][Full Text] [Related]
11. Safety and efficacy of lorcaserin: a combined analysis of the BLOOM and BLOSSOM trials. Aronne L; Shanahan W; Fain R; Glicklich A; Soliman W; Li Y; Smith S Postgrad Med; 2014 Oct; 126(6):7-18. PubMed ID: 25414931 [TBL] [Abstract][Full Text] [Related]
12. Lorcaserin: A review of its preclinical and clinical pharmacology and therapeutic potential. Higgins GA; Fletcher PJ; Shanahan WR Pharmacol Ther; 2020 Jan; 205():107417. PubMed ID: 31629010 [TBL] [Abstract][Full Text] [Related]
13. Serotonergic anti-obesity agents: past experience and future prospects. Halford JC; Boyland EJ; Lawton CL; Blundell JE; Harrold JA Drugs; 2011 Dec; 71(17):2247-55. PubMed ID: 22085383 [TBL] [Abstract][Full Text] [Related]
14. Efficacy and safety of lorcaserin in obesity: a systematic review and meta-analysis of randomized controlled trials. Singh AK; Singh R Expert Rev Clin Pharmacol; 2020 Feb; 13(2):183-190. PubMed ID: 31815555 [No Abstract] [Full Text] [Related]
15. Design and rationale for the Cardiovascular and Metabolic Effects of Lorcaserin in Overweight and Obese Patients-Thrombolysis in Myocardial Infarction 61 (CAMELLIA-TIMI 61) trial. Bohula EA; Scirica BM; Fanola C; Inzucchi SE; Keech A; McGuire DK; Smith SR; Abrahamsen T; Francis BH; Miao W; Perdomo CA; Satlin A; Wiviott SD; Sabatine MS Am Heart J; 2018 Aug; 202():39-48. PubMed ID: 29803985 [TBL] [Abstract][Full Text] [Related]
16. Lorcaserin (APD356), a selective 5-HT(2C) agonist, reduces body weight in obese men and women. Smith SR; Prosser WA; Donahue DJ; Morgan ME; Anderson CM; Shanahan WR; Obesity (Silver Spring); 2009 Mar; 17(3):494-503. PubMed ID: 19057523 [TBL] [Abstract][Full Text] [Related]
17. Lorcaserin and Renal Outcomes in Obese and Overweight Patients in the CAMELLIA-TIMI 61 Trial. Scirica BM; Bohula EA; Dwyer JP; Qamar A; Inzucchi SE; McGuire DK; Keech AC; Smith SR; Murphy SA; Im K; Leiter LA; Gupta M; Patel T; Miao W; Perdomo C; Bonaca MP; Ruff CT; Sabatine MS; Wiviott SD; Circulation; 2019 Jan; 139(3):366-375. PubMed ID: 30586726 [TBL] [Abstract][Full Text] [Related]
19. Discovery and development of 5-HT(₂C) receptor agonists for obesity: is there light at the end of the tunnel? Miller KJ; Wacker DA Future Med Chem; 2010 Dec; 2(12):1761-75. PubMed ID: 21428799 [TBL] [Abstract][Full Text] [Related]